Background: It is very important to understand and explore its carcinogenic effect for the study of effective therapeutic methods. Current studies have shown that ITGA2 plays an important role in some tumors, but it has not been reported in other human cancers, and no systematic pan-cancer analysis has been carried out.
Method: In this study, we used the online databases,for example GEPIA, THE HUMAN PROTEIN Atlas (THPA) , UALCAN, CPTAC and TIMER, to analyze ITGA2 in HUMAN tumors by analyzing TCGA and GEO medium datasets.
Results: Through the analysis of online database, we found that ITGA2 was differentially expressed in many kinds of tumors. There was a significant correlation between the differential expression of OS and DFS in hepatocellular carcinoma and Kidney renal clear cell carcinoma. At the same time, we also compared the degree of methylation between normal tissues and tumor tissues, and found that there were obvious methylation differences, such as liver cancer, cholangiocarcinoma, lung cancer and so on. We also evaluated the association between ITGA2 mutation and prognosis and found no significant association between ITGA2 mutation with OS. In addition, by predicting differences in the expression of ITGA2 in immunotherapy, we found that there were significant differences in the expression of ITGA2 in urothelial carcinoma, and explored the role and significance of ITGA2 in immune infiltration and biological process.
Conclusion: ITGA2 has been shown to play an important role in carcinogenesis in human tumors by pan-cancer analysis.